A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Exclusion Criteria

• •Significant cardiac disease.
• •Eye trauma or disease.
• •Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months prior to first dose of HGS1036.
• •Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of HGS1036.
• •Major surgery within 4 weeks of the first dose of HGS1036.
• •Prior organ or allogeneic stem cell transplant.
• •Non-healing or chronic wounds.
• •Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036.
• •Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of the first dose of HGS1036.
• •Active CNS involvement by primary or metastatic tumor.
• •Documented active infection requiring the use of systemic antibiotics.
• •Pregnancy or lactation.
• •Known HIV-positive serology, AIDS, or an AIDS-related illness.
• •Conditions likely to increase the potential for abdominal perforation or fistula formation.